Encephalopathy after whole-cell pertussis or measles vaccination: Lack of evidence for a causal association in a retrospective case-control study

Pediatric Infectious Disease Journal

Volumn 25, Issue 9, 2006, Pages 768-773

  Ray, Paula ^a   Hayward, Jean ^a   Michelson, David ^a   Lewis, Edwin ^a   Schwalbe, Joan ^a   Black, Steve ^a,f   Shinefield, Henry ^e   Marcy, Michael ^b   Huff, Ken ^b   Ward, Joel ^b   Mullooly, John ^c   Chen, Robert ^d   Davis, Robert ^d  

^a KAISER PERMANENTE   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c CENTER FOR HEALTH RESEARCH   (United States)

^d CENTERS FOR DIS CONTR AND PREV   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Pediatric Vaccine Study Center   (United States)

Author keywords

DTP; Encephalopathy; MMR; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; PERTUSSIS VACCINE;

ARTICLE; BRAIN DISEASE; CASE CONTROL STUDY; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH CARE ORGANIZATION; HOSPITALIZATION; HUMAN; INFANT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; MEDICAL RECORD; PERTUSSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

BRAIN DISEASES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; ENCEPHALITIS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEASLES-MUMPS-RUBELLA VACCINE; RETROSPECTIVE STUDIES;

EID: 33748333271     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000234067.84848.e1     Document Type: Article

References (21)

1. Malleson PN, Bennett JC. Whooping-cough admissions to a paediatric hospital over ten years. The protective value of immunisation. Lancet. 1977;1:237-239.
2. Miller DL, Alderslade R, Ross EM. Whooping cough and whooping cough vaccine: The risks and benefits debate. Epidemiol Rev. 1982;4:1-24.
3. Markowitz LE, Katz SL. Measles Vaccine. pp. 229-276.
4. Institute of Medicine. Adverse Effects of Pertussis and Rubella Vaccines. The National Academy of Sciences; 1991.
5. Romanus V, Jonsell R, Bergquist SO. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J. 1987;6:364-371.
6. Marcuse EK, Wentz KR. The NCES reconsidered: Summary of a 1989 workshop. National Childhood Encephalopathy Study. Vaccine. 1990;8:531-535.
7. Miller D, Wadsworth J, Ross E. Severe neurological illness: Further analyses of the British National Childhood Encephalopathy Study. Tokai J Exp Clin Med. 1988;13(suppl):145-155.
8. Alderslade R, Bellman MH, Rawson NSB, Ross EM, Miller DL. The National Childhood Encephalopathy Study: A Report on 1000 Cases of Serious Neurological Disorders in Infants and Young Children From the NCES Research Team. Department of Health and Social Security. Whooping Cough: Reports from the Committee on the Safety of Medicines and the Joint Committee on Vaccination and Immunization. London: Her Majesty's Stationery Office; 1981:79-169.
9. Miller D, Madge N, Diamond J, Wadsworth J, Ross E. Pertussis immunisation and serious acute neurological illnesses in children. BMJ. 1993;307:1171-1176.
10. Gale JL, Thapa PB, Wassilak SG, Bobo JK, Mendelman PM, Foy HM. Risk of serious acute neurological illness after immunization with diphtheria-tetanus- pertussis vaccine. A population-based case-control study. JAMA. 1994;271:37-41.
11. Committee on Infectious Diseases. The relationship between pertussis vaccine and central nervous system sequelae: Continuing assessment. American Academy of Pediatrics. Pediatrics. 1996;97:279-281.
12. Institute of Medicine. DPT Vaccine and Chronic Nervous System Dysfunction: A New Analysis. The National Academy of Sciences; 1994.
13. Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics. 1998;101:1-11.
14. Heininger U, Cherry JD, Stehr K, et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics. 1998;102:546-553.
15. Schmitt-Grohe S, Stehr K, Cherry JD, et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Dev Biol Stand. 1997;89:113-118.
16. Uberall MA, Stehr K, Cherry JD, et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Dev Biol Stand. 1997;89:83-89.
17. World Health Organization. Pertussis vaccines. Wkly Epidemiol Rec. 1999;74:137-143.
18. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink project: A new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics. 1997;99:765-773.
19. Weibel RE, Caserta V, Benor DE, Evans G. Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: A review of claims submitted to the National Vaccine Injury Compensation Program. Pediatrics. 1998;101:383-387.
20. Miller D, Wadsworth J, Diamond J, Ross E. Pertussis vaccine and whooping cough as risk factors in acute neurological illness and death in young children. Dev Biol Stand. 1985;61:389-394.
21. Rantala H, Uhari M. Occurrence of childhood encephalitis: A population-based study. Pediatr Infect Dis J. 1989;8:426-430.